Archive for January, 2018

  • aside

    Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with…

    by
  • aside

    Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology…

    by
  • aside

    Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the…

    by
  • aside

    Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks…

    by
  • aside

    Isofol to present at the 10th Annual Biotech Showcase Conference

    January 4 2017 Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief…

    by